UCB Pays $2 Billion Upfront for Candid’s BCMA‑Targeting T‑Cell Engager Cizutamig

Context UCB announced a definitive agreement to acquire Candid Therapeutics, a clinical‑stage biotech focused on multispecific T‑cell engager antibodies. The deal, valued at up to $2.2 billion, includes $2 billion paid at signing and potential milestone payments of $200 million. Closing is expected by late Q2 or early Q3 2026, subject to antitrust clearance.

Key Facts - Candid’s lead asset, cizutamig, is a bispecific antibody that binds B‑cell maturation antigen (BCMA) on plasma cells and CD3 on T‑cells, directing T‑cell‑mediated killing of BCMA‑expressing cells while limiting cytokine release. - The molecule has been tested in more than 100 patients with multiple myeloma and autoimmune diseases and is now in Phase I trials across ten autoimmune indications. - UCB CEO Jean‑Christophe Tellier said the acquisition demonstrates the company’s inorganic innovation strategy and adds a significant technological advancement to its pipeline. - Candid CEO Ken Song highlighted the company’s goal to redefine care for immune‑mediated diseases and noted that UCB’s immunology expertise will accelerate the development of its T‑cell engager portfolio. - The transaction expands UCB’s immunology platform, complementing recent deals such as the Antengene acquisition and reinforcing a focus on next‑generation biologics rather than a single asset.

What It Means For UCB, the purchase secures a promising bispecific antibody that could broaden its reach into B‑cell‑driven autoimmune disorders and multiple myeloma. Cizutamig’s design aims to achieve “immune reset” by eliminating pathogenic plasma cells while curbing inflammatory cytokine spikes, a balance that could differentiate it from existing therapies. If Phase I data confirm safety and efficacy, UCB may advance cizutamig into later‑stage trials, potentially adding a first‑in‑class option for patients with severe, underserved conditions.

The deal also signals continued consolidation in the biotech sector, as larger pharma firms acquire niche platforms to diversify pipelines. Stakeholders will watch regulatory clearance, early trial readouts, and how UCB integrates Candid’s broader T‑cell engager portfolio.

Looking ahead, the next milestone will be the antitrust decision and the first Phase I data from cizutamig’s autoimmune studies, which will shape the asset’s trajectory and UCB’s immunology strategy.